Law360, New York (September 17, 2007, 12:00 AM ET) -- Already facing a mountain of suits over Fosamax, Merck has protested a recent bid for certification of a dental monitoring class for patients taking the osteoporosis drug, arguing that the group has been unable to make a case that would justify the move.
On Friday, lawyers for Merck & Co. Inc. filed their objection in the U.S. District Court for the Southern District of New York, contending that plaintiffs’ recent request for class certification would be an inappropriate remedy under the law.
“Plaintiffs seek unprecedented class...
Merck Balks At Class Bid In Fosamax Case
To view the full article, take a free trial now.
